Is PXXLF or DIVO a better dividend investment in 2026?

PXXLF currently yields 769.23% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: PXXLF offers higher current income.

What is the dividend yield difference between PXXLF and DIVO?

PXXLF has a forward dividend yield of 769.23% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 762.74 percentage points.

Home › Compare › PXXLF vs DIVO

PXXLF vs DIVO: Dividend Comparison 2026

PXXLF yields 769.23% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PXXLF wins by $1993579.15M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PXXLF

● Live price

769.23%

Share price

$0.26

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1993579.18M

Annual income

$1,587,586,259,724.30

Full PXXLF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — PXXLF vs DIVO

📍 PXXLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PXXLF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PXXLF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PXXLF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PXXLF

Annual income on $10K today (after 15% tax)

$65,384.62/yr

After 10yr DRIP, annual income (after tax)

$1,349,448,320,765.66/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, PXXLF beats the other by $1,349,448,319,931.23/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PXXLF + DIVO for your $10,000?

PXXLF: 50%DIVO: 50%

100% DIVO50/50100% PXXLF

Portfolio after 10yr

$996789.61M

Annual income

$793,793,130,352.99/yr

Blended yield

79.63%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PXXLF buys

DIVO buys

No recent congressional trades found for PXXLF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPXXLFDIVO

Forward yield	769.23% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$1993579.18M ✓	$30.7K
Annual income after 10y	$1,587,586,259,724.30 ✓	$981.68
Total dividends collected	$1961258.26M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: PXXLF vs DIVO ($10,000, DRIP)

Year	PXXLF Portfolio	PXXLF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$87,623	$76,923.08	$11,349	$649.42	+$76.3K → PXXLF
2	$723,685	$629,928.66	$12,833	$688.83	+$710.9K → PXXLF
3	$5,636,611	$4,862,267.81	$14,459	$727.90	+$5.62M → PXXLF
4	$41,424,664	$35,393,490.07	$16,238	$766.49	+$41.41M → PXXLF
5	$287,421,912	$243,097,521.69	$18,179	$804.47	+$287.40M → PXXLF
6	$1,883,909,531	$1,576,368,085.04	$20,293	$841.71	+$1883.89M → PXXLF
7	$11,672,156,017	$9,656,372,818.42	$22,591	$878.14	+$11672.13M → PXXLF
8	$68,403,300,373	$55,914,093,435.45	$25,087	$913.65	+$68403.28M → PXXLF
9	$379,432,636,011	$306,241,104,611.84	$27,791	$948.18	+$379432.61M → PXXLF
10	$1,993,579,180,256	$1,587,586,259,724.30	$30,718	$981.68	+$1993579.15M → PXXLF

PXXLF vs DIVO: Complete Analysis 2026

PXXLF — Stock

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Full PXXLF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this PXXLF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PXXLF vs SCHD PXXLF vs JEPI PXXLF vs O PXXLF vs KO PXXLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.